Literature DB >> 19402071

Complexity of tumor vasculature in clear cell renal cell carcinoma.

Chao-Nan Qian1, Dan Huang, Bill Wondergem, Bin Tean Teh.   

Abstract

Clear cell renal cell carcinoma (CCRCC) is a highly vascularized cancer resistant to conventional chemotherapy and radiotherapy. Antiangiogenic therapy has achieved some effectiveness against this unique malignancy. The complexity of the tumor vasculature in CCRCC has led to differences in correlating tumor microvessel density with patient prognosis. The authors' recent findings demonstrated that there were at least 2 major categories of tumor vessels in CCRCC-namely, undifferentiated and differentiated-correlating with patient prognosis in contrasting ways, with higher undifferentiated vessel density indicating poorer prognosis, and higher differentiated vessel density correlating with better prognosis. Furthermore, the presence of pericytes supporting the differentiated vessels varied in CCRCC. The distributions of pericyte coverage and differentiated vessels in CCRCC were uneven. The tumor margin had a higher pericyte coverage rate for differentiated vessels than did the inner tumor area. The uneven distributions of pericyte coverage and differentiated vessels in CCRCC prompted the authors to revisit the mechanism of tumor central necrosis, which was also known to be a prognostic indicator for CCRCC. The discrepancy of prognostic correlation between protein and messenger RNA levels of vascular endothelial growth factor in CCRCC was discussed. The complexity of the tumor vasculature in CCRCC also led the authors to begin to re-evaluate the therapeutic effects of antiangiogenic agents for each type of tumor vessel, which will in turn significantly broaden understanding of tumor angiogenesis and improve therapeutic effect. (c) 2009 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19402071     DOI: 10.1002/cncr.24238

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  39 in total

Review 1.  Antiangiogenic treatments and mechanisms of action in renal cell carcinoma.

Authors:  Sylvie Négrier; Eric Raymond
Journal:  Invest New Drugs       Date:  2011-05-15       Impact factor: 3.850

2.  Rho GDP dissociation inhibitor-β in renal cell carcinoma.

Authors:  Christoph-Alexander von Klot; Natalia Dubrowinskaja; Inga Peters; Jörg Hennenlotter; Axel S Merseburger; Arnulf Stenzl; Markus A Kuczyk; Jürgen Serth
Journal:  Oncol Lett       Date:  2017-10-20       Impact factor: 2.967

3.  Von Hippel-Lindau mutations disrupt vascular patterning and maturation via Notch.

Authors:  Alexandra Arreola; Laura Beth Payne; Morgan H Julian; Aguirre A de Cubas; Anthony B Daniels; Sarah Taylor; Huaning Zhao; Jordan Darden; Victoria L Bautch; W Kimryn Rathmell; John C Chappell
Journal:  JCI Insight       Date:  2018-02-22

Review 4.  The tumor microenvironment in renal cell cancer.

Authors:  James W Mier
Journal:  Curr Opin Oncol       Date:  2019-05       Impact factor: 3.645

Review 5.  Hijacking the vasculature in ccRCC--co-option, remodelling and angiogenesis.

Authors:  Chao-Nan Qian
Journal:  Nat Rev Urol       Date:  2013-03-05       Impact factor: 14.432

6.  ERK5/BMK1 is a novel target of the tumor suppressor VHL: implication in clear cell renal carcinoma.

Authors:  Laura Arias-González; Inmaculada Moreno-Gimeno; Antonio Rubio del Campo; Leticia Serrano-Oviedo; María Llanos Valero; Azucena Esparís-Ogando; Miguel Ángel de la Cruz-Morcillo; Pedro Melgar-Rojas; Jesús García-Cano; Francisco José Cimas; María José Ruiz Hidalgo; Alfonso Prado; Juan Luis Callejas-Valera; Syong Hyun Nam-Cha; José Miguel Giménez-Bachs; Antonio S Salinas-Sánchez; Atanasio Pandiella; Luis del Peso; Ricardo Sánchez-Prieto
Journal:  Neoplasia       Date:  2013-06       Impact factor: 5.715

7.  Reduced expression of vasohibin-1 is associated with clinicopathological features in renal cell carcinoma.

Authors:  Guangning Zhao; Yuming Yang; Yang Tang; Ruifa Han; Yan Sun
Journal:  Med Oncol       Date:  2012-08-03       Impact factor: 3.064

8.  Dual Inhibition of Angiopoietin-TIE2 and MET Alters the Tumor Microenvironment and Prolongs Survival in a Metastatic Model of Renal Cell Carcinoma.

Authors:  May Elbanna; Ashley R Orillion; Nur P Damayanti; Remi Adelaiye-Ogala; Li Shen; Kiersten Marie Miles; Sreenivasulu Chintala; Eric Ciamporcero; Swathi Ramakrishnan; Sheng-Yu Ku; Karen Rex; Sean Caenepeel; Angela Coxon; Roberto Pili
Journal:  Mol Cancer Ther       Date:  2019-10-03       Impact factor: 6.261

9.  Microvessel density is high in clear-cell renal cell carcinomas of Ukrainian patients exposed to chronic persistent low-dose ionizing radiation after the Chernobyl accident.

Authors:  A M Romanenko; A Ruiz-Saurí; L Morell-Quadreny; G Valencia; A F Vozianov; A Llombart-Bosch
Journal:  Virchows Arch       Date:  2012-05-13       Impact factor: 4.064

Review 10.  The metastasis-promoting roles of tumor-associated immune cells.

Authors:  Heath A Smith; Yibin Kang
Journal:  J Mol Med (Berl)       Date:  2013-03-21       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.